Topical heat shock protein 70 prevents imiquimod-induced psoriasis-like inflammation in mice
- 89 Downloads
Psoriasis is a chronic inflammatory skin disease with systemic manifestations and potential genetic etiology. The newest treatments utilize antibodies against one of several cytokines known to underlie the inflammatory signaling molecules that produce the skin and systemic symptoms. However, these agents must be regularly injected, and they may compromise the normal responses of the immune system. Furthermore, they do not address the causes of the abnormal immunoregulatory responses of the disease because the etiology is not yet completely understood. In this short-term treatment study, the potential anti-inflammatory activity of an alfalfa-derived Hsp70-containing skin cream (aHsp70) was tested on imiquimod (IMQ)-induced psoriasis-like lesions in wild-type mice. Treatment of the mice with the aHsp70 skin cream simultaneously with the imiquimod application mitigated the induction of psoriatic-like lesions and correlated with altered expression of various skin cytokines.
KeywordsHsp70 Alfalfa Psoriasis Skin cream Anti-inflammatory
This research was supported by the Cleveland Clinic (Cleveland, OH), National Psoriasis Foundation (discovery grant 2016 to U. C.) and Alfa Biogene International, B.V. (Baarn, Netherlands).
Compliance with ethical standards
All experiments were approved by the institutional animal care and use.
- Bukau B and Mayer MP (2005) Recovery of a heat shock protein. Patent publication #EP 1531160 A1, https://patents.google.com/patent/EP1531160A1/en?oq=EP+1531160+A1
- Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Stâhle M, Nestle FO, Girolomoni G, Kreuger JG (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785–1796. https://doi.org/10.1038/jid.2010.103 CrossRefPubMedGoogle Scholar
- Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:722–733. https://doi.org/10.1016/j.jaad.2003.11.066 CrossRefPubMedGoogle Scholar
- Lowes MA, Suarez-Farinas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227–255. https://doi.org/10.1146/annurev-immunol-032713-120225 CrossRefPubMedPubMedCentralGoogle Scholar
- Monin L, Gaffen SL (2017) Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a028522
- Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012;7:385–422 https://doi.org/10.1056/NEJMra0804595
- Seifarth F and Lax J (2014) Filtration of a liquid comprising a plant stress protein. Publication # EP2417153 B1. https://www.google.com/patents/EP2417153B1?cl=en
- Sharma J, Balakrishnan L, Datta KK, Sahasrabuddhe NA, Khan AA, Sahu A, Singhal A, Getnet D, Raju R, Chatterjee A, Gowda H, Keshava Prasad TS, Shankar S, Pandey A (2015) A knowledgebase resource for interleukin-17 family mediated signaling. J Cell Commun Signal 9:291–296. https://doi.org/10.1007/s12079-015-0297-3 CrossRefPubMedPubMedCentralGoogle Scholar
- van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Comelissen F, Mus AM, Florencia E, Prens EP, Lubberts E (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL23/IL17 axis. J Immunol 182:5836–5845. https://doi.org/10.4049/jimmunol.0802999 CrossRefPubMedGoogle Scholar
- Wu JJ, Lynde CW, Kleyn CE, Iversen L, van der Walt JM, Carvalho A, Kirby B, Bissonette R (2016) Identification of key research needs for topical therapy treatment of psoriasis—a consensus paper by the International Psoriasis Council. J Eur Acad Dermatol Venereol 30:1115–1119. https://doi.org/10.1111/jdv.13614 CrossRefPubMedGoogle Scholar
- Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ (2000) Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 106:1171–1176. https://doi.org/10.1067/mai.2000.110922 CrossRefPubMedGoogle Scholar